Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single-dose Administration of GR2102 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2102
NCT06313697 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Single-dose Administration of GR2102 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2102
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 23, 2024
- Completion date
- December 6, 2025
- Enrollment
- 132 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.